Dr. Anders Fink-Jensen: GLP-1 Therapy for Alcohol Use Disorder | Ep. 16

In this episode of The GLP-1 Podcast Show, I speak with Dr. Anders Fink-Jensen, Professor of Psychiatry at the University of Copenhagen and a consultant psychiatrist, about the emerging role of GLP-1 receptor agonists in addiction treatment. We examine the clinical observations that initiated this research, findings from a randomized trial of semaglutide for alcohol use disorder, possible effects on craving, dosing considerations, and the evidence still needed before broader clinical use. Listen now on all major platforms.

"Semaglutide reduced both total alcohol consumption and the number of heavy drinking days."

Meet the guest: Dr. Anders Fink-Jensen is a professor at the University of Copenhagen and a consultant psychiatrist. His research focuses on psychopharmacology, addiction, severe mental illness, and the clinical evaluation of GLP-1 receptor agonists in people with alcohol use disorder. Listen to Dr. Anders Fink-Jensen on The GLP-1 Podcast Show, available on all major platforms.

Want to stay up to date on the latest GLP-1 research and updates? Subscribe and never miss an episode.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (02:06) Introduction
• (03:03) Origins of addiction research
• (07:24) Semaglutide trial design
• (12:06) Alcohol use outcomes
• (18:10) Patient selection
• (23:33) Future clinical research
• (27:06) Closing thoughts

The GLP-1 Podcast Show is trusted and supported by innovative companies like:

- ZentrixOS

- Zentrix Insights

- Elevate

- WiseVAs

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The GLP-1 Podcast Show

Instagram: The GLP-1 Podcast Show

LinkedIn: The GLP-1 Podcast Show

YouTube: The GLP-1 Podcast Show

Facebook: The GLP-1 Podcast Show

TikTok: The GLP-1 Podcast Show